NCT07518771 is a Phase 1 clinical trial of PA-001 in COVID - 19, sponsored by PeptiDream Inc..

Who is sponsoring NCT07518771?

NCT07518771 is sponsored by PeptiDream Inc..

What drugs are being tested in NCT07518771?

Interventions in NCT07518771: PA-001.

What condition does NCT07518771 study?

NCT07518771 studies COVID - 19.

Is NCT07518771 still recruiting?

NCT07518771 is currently completed. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT07518771

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PA-001 Ph.1 Study in Healthy and Elderly Subjects

Completed Phase 1 Last updated 9 April 2026

What this trial tests

Phase 1 trial testing PA-001 in COVID - 19 in 47 participants. Completed in 2 June 2025.

Timeline

30 July 2024

Primary endpoint
2 June 2025

2 June 2025

Quick facts

Lead sponsor	PeptiDream Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	47
Start date	30 July 2024
Primary completion	2 June 2025
Estimated completion	2 June 2025
Sites	1 location across United States

Drugs / interventions tested

PA-001

Conditions studied

COVID - 19 — all drugs for COVID - 19 →

Sponsor

PeptiDream Inc.

Who can join

18 and older, any sex, with COVID - 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts. The principal aim of this study was to obtain safety and tolerability data when PA-001 is administered IV as single and multiple doses to healthy subjects. This information, together with the PK data, will help establish the doses and dosing regimen suitable for future studies in patients. The study also investigated the effects of age on the PK of PA-001 prior to patient studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID - 19

Currently open trials in the same condition.

NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
NCT07150871 — Impact of Covid-19 on Syphilis · active not recruiting
NCT07204366 — Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Stu · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07518771 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PeptiDream Inc.
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07518771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing